| Company Name | Novartis (Taiwan) Co., Ltd. |
|---|---|
| Protocol Number | CICL670ATW03 |
| Title of Study | A Prospective, Non-interventional, Multi-center, Surveillance Study to Observe the Tolerability of Exjade® (Deferasirox) in Patients with Myelodysplastic Syndrome (MDS) for Chronic Transfusion-Related Iron Overload |
| Primary Objective | To explore tolerability of Exjade® as chelation therapy through measuring AE-related discontinuation rate in routine clinical practice in MDS patients at 6 months. |
| Number of Sites | 10 |
| Period of Study | From：Aug.1, 2015 to：Aug. 31, 2019 |
| Number of Patients | 100人 |
| IRB Approval Date | Sep. 17, 2015 (1st IRB approval date) |
| Publication Plan / Date | Aug. 31, 2020 |
